

THE CONTENT OF THIS ANNOUNCEMENT HAS BEEN PUBLISHED USING EQUITY STOCK CODE (STOCK CODE: 853) ON 5 MARCH 2024 AND IS NOW REPUBLISHED USING DEBT STOCK CODES (STOCK CODE: 40168 AND 40720) FOR THE DEBT HOLDERS INFORMATION.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

ESTIMATED ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023

This announcement is made by MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform holders of the Company’s shares and securities and potential investors that, the preliminary assessment based on the unaudited consolidated financial statements of the Group and other currently available information is as follows:

For the twelve months ended 31 December 2023 (the “**Reporting Period**”), notwithstanding the influence of unfavorable factors in the complex and volatile domestic and overseas environment, the Group still achieved a year-on-year increment in revenue (excluding the effect of exchange rate on such revenue increment and the revenue growth rates shown in this announcement) of over 15%. Such increase was principally attributable to:

- (i) market share of independent listed subsidiaries of the Group increased further and rapid growth in their sales revenues were achieved, driven by the launch of new products and commercialization promotion. Among which, revenue from Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd.* (endovascular and peripheral vascular devices business) (“**EV MedTech**”) grew year-on-year by over 32%, revenue from MicroPort NeuroTech Limited* (neurovascular business) (“**MicroPort NeuroTech**”) grew year-on-year by approximately 22%, revenue from MicroPort CardioFlow Medtech Corporation* (heart valve business) (“**CardioFlow Medtech**”) grew year-on-year by approximately 31% to 36%, and revenue from Shanghai MicroPort MedBot (Group) Co., Ltd. (“**MicroPort MedBot**”) (surgical robot business) also achieved a year-on-year growth over 350%;

- (ii) other major businesses within the Group has further consolidated their competitive advantages and achieved a steady growth in revenue;
- (iii) as commercialization continued to make progress, revenue from emerging businesses recorded an exponential growth.

During the Reporting Period, the Group was estimated to record losses of not greater than USD580 million (as compared to losses for last year of approximately USD588.1 million) due to the improved profitability brought about by the significant increase in revenue from the Group's major businesses, as well as the Group's proactive implementation of resource focus and cost control measures to continuously improve operational efficiency and profitability. The net loss excluding one-time and/or non-cash provisions and losses was not greater than US\$436.0 million (as compared to the net losses excluding the one-off and/or non-cash provisions and losses for last year of approximately USD502.5 million), representing a year-on-year decrease over 13%. The abovementioned one-time and/or non-cash provisions and losses mainly includes impairment losses on equity-accounted investees and goodwill, share-based payment compensation and interest costs on preferred shares issued by subsidiaries.

In the future, the Group will continue to pay high attention to the health of its financial position and the adequacy of its cash flow, and endeavor to significantly reduce its losses and achieve breakeven in the coming years by focusing on its business, increasing its revenue and lowering the expenses such as research and development.

As at the date of this announcement, the Company is still in the process of preparing and completing the annual results of the Group for the twelve months ended 31 December 2023 (the “**2023 Annual Results**”). The information contained in this announcement is a preliminary assessment made by the Board based on the latest unaudited consolidated financial statements of the Group which have not been audited or reviewed by the independent auditors or audit committee of the Company. Holders of the Company's shares and securities and potential investors are advised to read the Company's announcement for the 2023 Annual Results carefully, which is expected to be published by the end of March 2024. Holders of the Company's shares and securities and potential investors are advised to exercise caution when dealing in the shares and securities of the Company.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 5 March 2024

As at the date of this announcement, the executive Director of the Company is Dr. Zhaohua Chang; the non-executive Directors are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Ms. Weiqin Sun, Dr. Qiyi Luo and Mr. Bo Peng; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* For identification purpose only